about
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma.Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma ModelsA recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression.A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivoThe BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs.Molecular profiling of childhood cancer: Biomarkers and novel therapiesTherapeutic targeting of apoptosis pathways in cancer.Anti-apoptosis mechanisms in malignant gliomas.Genomic Insights into Diffuse Intrinsic Pontine Glioma.Antibody therapy for pediatric leukemia.Reduced incidence of second solid tumors in survivors of childhood Hodgkin's lymphoma treated without radiation therapy.Outcomes in multifocal neuroblastoma as part of the neurocristopathy syndrome.The international diffuse intrinsic pontine glioma registry: an infrastructure to accelerate collaborative research for an orphan disease.Ganglioglioma Arising From Desmoplastic Medulloblastoma: A Case Report and Review of Literature.Targeting the inhibitor of apoptosis proteins as a novel therapeutic strategy in medulloblastoma.Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins.Neonatal Sweet syndrome: a potential marker of serious systemic illness.False-positive MIBG scans with normal computed tomography imaging in patients with high-risk neuroblastoma.Upper airway obstruction induced by a caustic substance found responsive to nebulised adrenaline.Australian Paediatric Surveillance Unit study of haemoglobinopathies in Australian children.Retinoic acid may increase the risk of bone marrow transplant nephropathy.Investigating the biology of relapsed acute leukemia: Proceedings of the Therapeutic Advances for Childhood Leukemia & Lymphoma (TACL) Consortium Biology Working Group.Comprehensive Analysis of Hypermutation in Human Cancer.Never say never.A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH.Case Report of Spontaneous Resolution of a Congenital Glioblastoma.Too many targets, not enough patients: rethinking neuroblastoma clinical trials.Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma.Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma.Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.The Development of Delta: Using Agile to Develop a Decision Aid for Pediatric Oncology Clinical Trial Enrollment.Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries.Enrolment in paediatric oncology early-phase clinical trials: The health-care professionals' perspectiveIntegration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancerThe Development of Delta: Using Agile to Develop a Decision Aid for Pediatric Oncology Clinical Trial Enrollment (Preprint)Oral malignant gastrointestinal neuroectodermal tumour with junctional component mimicking mucosal melanomaBrief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade gliomaGermline deletion of in familial acute lymphoblastic leukemiaPCR for monoclonal gene rearrangements can differentiate infantile acute lymphoblastic leukemia from cytomegalovirus infection
P50
Q27853237-B79D9E41-97E3-42A9-A995-233B9E905C60Q28468398-38C771F9-A59E-4AC5-B82E-0C80F4E5A73FQ34369388-B7515281-2E98-42FC-BA70-D6A94E0595C5Q34519715-08E04CBC-3499-48DA-AA67-534A69721AD0Q35133408-A5D3D53A-E8CE-40D9-838E-2EF5DA60431AQ36169695-CA69C174-D47F-40B6-9C53-F2866AD9A201Q36250783-E6E75137-8BF6-4762-A4C2-C02F93C9FBF3Q37016846-2C4F8CC3-8988-4F76-9FEE-5FC2ECD8037BQ37059590-41EC19AB-60C8-418C-9423-4BE5CAEF25AAQ37723508-0B8EE45C-1D5E-4A9D-9722-57D48AA46180Q37725578-8FFD1F0A-710D-4C2C-962E-6344A965A44AQ37851758-1F57F3D5-7EF2-4A9D-A3A9-787E1F189A8AQ38234788-44B75295-D3B0-4A07-8A5A-24A3F1A5A70BQ38374138-4D0E9DCC-6D12-4D7D-8989-4C84521B90E1Q39148588-8B8F42CE-657D-4329-9B9F-42A804AD568AQ39271333-34CBD1CC-47A4-4125-B884-4D2D9E246643Q39954297-F9E24ED9-4E37-4247-BD44-5D809C0C33E2Q40290108-8211EF79-88CD-4DA3-8069-0FAE216F9F6EQ43250049-74465D48-8C06-4947-875D-4BA70227524CQ43910114-288112D0-D536-490B-AB0E-4B670DFB5A3CQ44290286-AB597DF1-ED66-4D86-844F-A6027AE564DBQ45272407-BDA801D0-9FFB-402A-8BA5-D4088D68F41BQ46355299-D3BEB352-D95B-4C1F-9022-D069AE5406CCQ46592106-E7FC0F27-9B9A-4F13-BE8A-EFD80EA989EDQ47574014-138EC39F-C093-42BC-869F-94AD4586587CQ47660672-52F9202C-1838-475F-8039-1B8B17F694B9Q48829806-5B0B3C57-AF1B-4EA5-9063-3ABFEB015BEEQ52597787-E5FEB7DE-9915-4211-83D4-BB09AEDF1894Q52684145-C070ED55-42A7-4DCD-A5DE-5F53BE2C9B37Q53705750-5CC89F37-79C4-474D-85DA-4A74D12D1854Q53819925-70DC3A3C-D8A8-4281-95BA-5D5626EA44DEQ55256888-CE00C464-129C-4E20-AB5F-1FFC39DF6059Q55456557-F938556C-B131-4D3B-855F-280D6DAB4850Q56983576-E32235DB-D6E8-421D-B2B5-C3BAB190EC2DQ57287736-5B9BACB2-C339-424C-A33E-660D37746197Q57910550-717D23D7-F31C-4E30-9629-697A7174D6AAQ60456241-5FD85184-D295-4265-AD60-D8C0FDF1F8F0Q62820070-E485FA38-B47D-4CCA-B9EC-253EFAF94C8FQ64083344-5D9F1E4F-146A-4667-9DA8-AA10D029813AQ80996775-AB824EC7-025F-4911-9C29-CF1FC2BB990B
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0001-7451-7916
@en
name
David S Ziegler
@ast
David S Ziegler
@en
David S Ziegler
@nl
type
label
David S Ziegler
@ast
David S Ziegler
@en
David S Ziegler
@nl
prefLabel
David S Ziegler
@ast
David S Ziegler
@en
David S Ziegler
@nl
P106
P21
P31
P496
0000-0001-7451-7916